scholarly journals Ranitidine-induced junctional rhythm in a pediatric patient: A rare and potentially harmful side effect

2020 ◽  
Vol 13 (2) ◽  
pp. 179 ◽  
Author(s):  
Dan Morgenstern-Kaplan ◽  
Vanessa Escamilla-Leyva ◽  
CarlosManuel Aboitiz-Rivera ◽  
Ruben Blachman-Braun
2011 ◽  
Vol 18 (4) ◽  
pp. 232-234 ◽  
Author(s):  
E Dedeoglu ◽  
A Uzun ◽  
B Bayram ◽  
E Cevik ◽  
D Arslan

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii423-iii424
Author(s):  
Christopher Kuo ◽  
Kaaren Waters ◽  
Clement Cheung ◽  
Ashley Margol

Abstract Temozolomide is a chemotherapeutic agent commonly used in the treatment of central nervous system tumors. While there are case reports of temozolomide associated central diabetes insipidus (CDI) in adults, this has not been reported in children. We describe the first case of temozolomide associated CDI in a pediatric patient. The patient was a previously healthy 12yr old male diagnosed with anaplastic astroblastoma. He underwent gross total resection of the lesion and was subsequently treated with focal radiation therapy and concurrent temozolomide. On day 21 of therapy he developed thrombocytopenia, severe polyuria and polydipsia. Temozolomide was held and he underwent a preliminary evaluation for CDI. Initial laboratory findings were concerning for CDI, and he was admitted for further work-up and to assess the need for desmopressin. Additional laboratory tests demonstrated normal anterior pituitary function and his serum sodium normalized when allowed to drink to thirst, mitigating the need for desmopressin. Temozolomide was not restarted and the symptoms of polyuria and polydipsia resolved and did not recur. Upon review, the tumor did not involve the pituitary or hypothalamus. Additionally, these areas were not involved in the irradiation field. CDI is a rare but clinically significant side effect of temozolomide, reported in adults. Given this is the first report of CDI secondary to temozolomide in a pediatric patient, we speculate that this is likely under-recognized in children. Prompt recognition and treatment is necessary to prevent severe sequelae of hypernatremia.


1975 ◽  
Vol 86 (5) ◽  
pp. 804 ◽  
Author(s):  
Madu Rao ◽  
Phillip Steiner ◽  
Minerva S. Victoria

PEDIATRICS ◽  
1983 ◽  
Vol 71 (5) ◽  
pp. 839-840
Author(s):  
RICHARD D. COLAVITA ◽  
KAREN M. GAUDIO ◽  
NORMAN J. SIEGEL

Captopril is known to be effective for the control of hypertension in adults.1,2 Several recent reports have described the efficacy of this drug in children3,4 and neonates.5 Side effects include neutropenia, proteinuria, rashes, ageusia, hypotension, and hyperkalemia. Farrow and Wilkinson6 described a case of reversible renal failure during therapy with captopril in a young woman with severe hypertension secondary to renal artery stenosis. However, renal failure is not a well-appreciated side effect of this drug and has not been described previously in a pediatric patient during treatment with captopril. We report two cases in which a reversible decline in renal function occurred in children being treated with captopril.


Author(s):  
Wei Pu ◽  
Jiaxu Wang ◽  
Yuefeng Xin ◽  
Junyang Li ◽  
Guangwu Zhou ◽  
...  

The three high-performance indicators (low retrace tolerance, long life and low vibration) of N–N type planetary gear apparatus with small tooth number difference (abbrev “N–N–PGA”) are hardly achieved simultaneously until recently. At present, the root cause analysis (RCA) and TRIZ are considered to be comprehensive and systematic new theories for technological innovation, which provides a new way to figure out the conundrum existed in the N–N–PGA. In the present study, the “root cause” of the problem is proposed with the RCA approach and two contradictions existed in the N–N–PGA have been revealed: Harmful side effect and stability of composition; harmful side effect and durability of a moving object. Besides, two reasonable principles (“Dynamicity” and “Composite materials”) for the N–N–PGA design recommended by the TRIZ method are used to eliminate these contradictions. In addition, a prototype of the obtained new type N–N–PGA design is developed for experimental testing. The obtained result demonstrates the capability of the above method for obtaining low retrace tolerance, long life, and low vibration.


2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Zachary Orlins ◽  
Brian Barnett

Here, we present the case of a patient who initiated risperidone and developed persistent tachycardia, which was exacerbated by subsequent administration of paliperidone palmitate despite treatment with propranolol. This patient’s experience emphasizes the need for psychiatrists to regularly monitor vital signs after risperidone/paliperidone initiation, dosage increase, or overdose to identify and appropriately manage this potentially harmful side effect. Increasing clinician awareness of this rare side effect will help protect patients with serious mental illness who regularly rely upon these medications, particularly in their long-acting injectable formulations.


2009 ◽  
Vol 36 (12) ◽  
pp. 2780-2787 ◽  
Author(s):  
GIANFRANCO FAVIA ◽  
GIOVANNI PIETRO PILOLLI ◽  
EUGENIO MAIORANO

Objective.Osteonecrosis of the jaws (ONJ) is a well known side effect of bisphosphonate therapies in patients with multiple myeloma or other malignancies. Its real incidence is still undetermined, and only few cases of ONJ in patients taking bisphosphonates for non-oncologic diseases have been reported. It was postulated that the clinical features, predisposing factors, and treatment outcome of this subset of patients might be different from those of oncologic patients.Methods.Over a 4 year period, a total of 102 bisphosphonate-treated patients affected by ONJ were identified. Among these, 24 patients underwent bisphosphonate therapy for non-neoplastic disease and their profile was analyzed.Results.In this study cohort, bisphosphonates had been administered mainly for postmenopausal osteoporosis (20/24 patients, 83.3%), the duration of therapy until presentation of ONJ ranging from 11 to 40 months and the most common triggering event being dentoalveolar surgery. All patients were nonsmokers; 6 manifested multiple ONJ lesions and only 3 of them had possible comorbidities. Surgical debridement was performed in 19 patients for a total of 22 lesions, which were individually considered in the followup. The latter showed complete remission of ONJ in 21/22 lesions.Conclusion.Although it might be considered a rare condition in non-oncologic patients, ONJ is a harmful side effect of bisphosphonate therapies. Clinicians must be aware of this entity, inform patients of the risks related to dental surgery, and possibly undertake adequate preventive measures.


1996 ◽  
Vol 135 (1) ◽  
pp. 146-147 ◽  
Author(s):  
E. Papadavid ◽  
J. Yell ◽  
T.J. Ryan
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document